Lowers the risk of hospitalization for heart failure. ANDA 211582, held by Zydus Pharms. Dapagliflozin.
As of Nov 15, 2026, ANDA 211582 (Dapagliflozin), held by Zydus Pharms, was first approved by FDA on Apr 6, 2026, with 0 approved supplements and 0 published complete response letters.
Dapagliflozin tablets are indicated: To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors. As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Dapagliflozin tablets are not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.. Dapagliflozin is not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2. Dapagliflozin is likely to be ineffective in this setting based upon its mechanism of action.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 6, 2026 | Original application | Approved | None posted |
| Dapagliflozin5MG · tablet;oral | Dapagliflozin | Rx |
| Dapagliflozin10MG · tablet;oral | Dapagliflozin | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters